Therefore, in the present study, we investigated the combined effects of ruxolitinib and calcitriol in other molecular subtypes of breast cancer cells, including the luminal A subtype MCF-7, HER2-enriched subtype SKBR3, and TN subtype MDA-MB-468, which were not covered in our previous study. This evidence concerns the gene ERBB2 and breast carcinoma.